The Fellow on Call: The Heme/Onc Podcast

This week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial therapy; for patients who are able to undergo a transplant, we have consolidated their disease with a transplant; and now, we want to maintain that response using a lower dose of therapy, all while trying to minimize toxicity and maximize the patient’s quality of life. We discuss this in detail in this week’s episode!
Content:
- Why is lenolidomide (revlimid) our current standard of care?
- What data do we have to add anti CD38 antibodies?
- How is MRD being considered in this space?
** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

Throughout this series, we have discussed that for eligible patients, the current standard of care is to take patients for autologous stem cell transplant as consolidation for their multiple myeloma. In this reboot episode, we sit down with two incredible hematologists who specialize in transplant to discuss the real-life decision-making that goes into evaluating each patient. We are so excited to welcome two special guests this week, Dr. Shonali Midha and Dr. Amar Kelkar, joining us from the Dana-Farber Cancer Institute in Boston!
Content:
- What goes into determining if a patient is transplant eligible?
- What counseling is provided to patients?
- Approach to melphalan dosing
- How does apheresis work?
- What agents are used to help mobilize stem cells?
- How many stem cells do we need to collect?
- Does how much therapy one has received affect their collection?
- Is there still a role for transplant in today's world?
- Is there a role for an "MRD-adapted" approach to treatment?
- Is there a role for a second transplant in patients who have relapsed?
- Is there a role for allogeneic stem cell transplants in myeloma?
A huge THANK YOU to our guests, Dr. Shonali Midha and Dr. Amar Kelkar, both of the Dana-Farber Cancer Institute!
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

This week, we discuss the role of the “consolidation” phase of treatment in multiple myeloma, focusing on three key trials: IFM 2009, DETERMINATION, and the MIDAS Trial.
Content:
- What is the role of autologous stem cell transplant in the management of multiple myeloma?
- How did we get to our current standards of care?
- How is minimal residual disease (MRD) fitting into our treatment paradigm?
** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

This week, we are so excited to share the first of our Career Development Series episodes, developed in partnership with The American Society of Hematology , The ASH Trainee Council, and Hematopoiesis!
For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!
This time, we welcome two amazing guests, Dr. Hetty Carraway, Director of the Leukemia Program and the Vice Chair of Strategy and Enterprise Development at the Taussig Cancer Institute at The Cleveland Clinic, and Dr. Alfred Lee, Chief of Classical Hematology at Yale School of Medicine, for our inaugural episode where we discuss the importance of mentorship and ask them all the questions most of us have always wondered but are too afraid to ask our mentors. A MUST listen for all trainees!
** This episode is created in partnership with The American Society of Hematology (hematology.org), The ASH Trainee Council (https://www.hematology.org/education/trainees/fellows/trainee-council), and Hematopoeisis (https://www.hematology.org/education/trainees/fellows/hematopoiesis)
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube

This week, we begin our discussion about treatment of multiple myeloma, focusing on the first-line setting. Once again, a lot has changed in this space over the last few years, most notably the standards of care (now quadruplet regimens instead of triplet regimens!). We break down the data and how to help you practically approach your treatment planning for your patient with newly diagnosed multiple myeloma.
Content:
- What are the phases of treatment for multiple myeloma
- What are our current treatment standards of care?
- How do we select the agents to include in our first-line regimens?
- How do we stratify patients into quadruplet vs. triplet eligible? What about transplant eligible vs. ineligible?
** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube